<DOC>
	<DOC>NCT01653327</DOC>
	<brief_summary>- The primary objective is to determine the reduction in pain score by ketamine mouthwash compared to placebo in head and neck cancer patients with refractory mucositis. - The secondary objectives are to describe the duration of analgesia and adverse effects associated with ketamine and placebo.</brief_summary>
	<brief_title>Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Subjects diagnosed with head and neck tumors (any histology) receiving ongoing chemoradiation or radiation therapy Subjects with mucositis pain refractory to topical management, defined as any selfreported pain score of &gt; 2 in the 24 hours prior to enrollment despite use of topical agents as prescribed Age â‰¥ 18 years Ability to understand and willingness to consent and to sign consent form Active substance abuse at time of registration (alcohol, drugs, nonprescription use of controlled substances) Subjects with history of allergic reactions to ketamine Persistent oral bleeding: &gt; 15 mL (estimated) per day Pregnancy or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>mucositis</keyword>
	<keyword>head and neck</keyword>
	<keyword>cancer</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>oral</keyword>
	<keyword>pain</keyword>
</DOC>